• Oral tetracyclines, particularly minocycline and doxycycline, may be prescribed for moderate-to-severe rosacea; however, their use is associated with systemic AEs 1, 3 • A novel, foam formulation of minocycline -FMX-103 -has been developed to facilitate local application and bioavailability of minocycline while preserving its efficacy for the treatment of rosacea • This was a randomized, multicenter, double-blind study evaluating the safety and efficacy of 2 different doses of the topical minocycline foam, FMX-103 1.5% and 3%, in the treatment of papulopustular rosacea, as compared with vehicle Methods • Phase 2, randomized, multicenter (18 sites in Germany), double-blind, vehiclecontrolled clinical trial • Evaluated the safety and efficacy of 2 doses of a topical once-daily minocycline foam (FMX-103 1.5% and 3%) compared with vehicle foam in the treatment of moderate-to-severe papulopustular rosacea ( Figure 1) -Subjects were randomized 1:1:1 to receive treatment once daily (in the evening) for 12 weeks -Safety and efficacy evaluations were performed at week 2, 4, 8, and 12, with an additional safety follow-up visit at week 16 A total of 233 subjects were randomized; however, 1 subject in the FMX-103 3% group did not receive treatment and was not included in the intent-to-treat analysis.
Results
• 232 subjects were randomized and received at least one dose of study drug (ITT population)
-201 (86.6%) subjects completed 12 weeks of treatment and the follow-up visit
• Baseline demographics and disease characteristics are shown in Table 1 -~50% to 60% of subjects had severe rosacea; the mean number of inflammatory lesions ranged from 30.6 to 34.5 • At week 12, both FMX-103 1.5% and 3% doses significantly reduced the number of papules and pustules vs vehicle (P<.001) ( Figure 2A) -Significant reduction in lesion count was observed as early as week 2
• The corresponding percentage reductions in inflammatory lesions were 61.4% and 55.5% for FMX-103 1.5% and 3%, respectively, vs 29.7% for vehicle at week 12 (P<.001) ( Figure 2B ) • Significantly more FMX-103 1.5% and 3% subjects achieved ≥2-grade improvement in IGA ( Figure 3A) and IGA score of "clear" or "almost clear" vs vehicle at week 12 ( Figure 3B) -Significantly more FMX-103 subjects had improvement of ≥2 IGA grades as early as week 4
• There was no statistically significant difference between the FMX-103 1.5% and 3% groups 
Safety
• Both FMX-103 1.5% and 3% doses appeared to be generally safe and well tolerated, with no reported treatment-related systemic AEs -Overall, 47% (109/232) of subjects reported ≥1 TEAE ( Table 2) -The most common AEs (≥2% of subjects) included nasopharyngitis, urinary tract infection, cystitis, and bronchitis ( Table 3) -11 (4.7%) subjects reported treatment-related TEAEs; 9 had treatmentrelated dermal reactions ( Tables 2, 4) -Serious TEAEs were reported in 4 subjects (3 in FMX-103 groups and 1 in vehicle group) ( Tables 2, 4) -4 subjects discontinued the study due to TEAEs; only 3 subjects discontinued due to dermal-related TEAEs (skin and subcutaneous tissue disorders) (Tables 2, 4) Eczema, rosacea, pruritus, and skin burning sensation were classed as skin and subcutaneous tissue disorders (dermal related); burning sensation was classified as a nervous system disorder.
Conclusions
• At week 12, both FMX-103 1.5% and FMX-103 3% were significantly better than vehicle in -Reducing the number of papules and pustules -Improving IGA score by ≥2 grades -Achieving IGA of "clear" or "almost clear" (score 0 or 1)
• Both FMX-103 doses appeared to be generally safe and well tolerated, with no reported treatment-related systemic AEs -Only 3 subjects discontinued the study due to dermal-related TEAEs
• These results indicated that FMX-103 appeared to be an effective, safe, and well tolerated treatment for moderate-to-severe papulopustular rosacea
• The results support further investigation in a larger, Phase 3 clinical trial
